explore -WSS

explore

author：knowledge 2025-09-03 15:18:39 - browse：1354

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： What affirmative action's end means to a medical student

knowledge

WSS

Drug cartel violence flares in western Mexico after vigilante leader's killing

Twill hunts for pharma partner to market its depression app

Crowdfunding for unproven stem cell procedures spreads misinformation

UpToDate has a racism problem: Dr. Stanley Goldfarb

Hubble vs. James Webb telescope images: See the difference

ER docs worry over extreme heat as a 'mass casualty event'

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Continuity nursing helped my family in our darkest PICU moments

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Psychedelics group wrestles with new pharma identity

Hubble vs. James Webb telescope images: See the difference

Affirmative action in medical school literally saved lives

The wait for US passports is creating travel purgatory and snarling summer plans

What does generative AI mean for health care? We asked experts

A strong 6.5

In Memoriam: Notable people who died in 2023

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

hotspot

Canadians with cystic fibrosis outlive Americans by a decade

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

A look at other Americans who have crossed into North Korea over the years

Security flaws in third

Robert Kennedy Jr.'s presidential campaign attracts GOP

entertainment

knowledge

explore

entertainment